FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

l	OMB APPROVAL											
l	OMB Number:	3235-0287										
l	Estimated average burden											
l	hours per response.	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of David W	Reporting Person*		2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]								(Ched	k all applic Directo	able)	Perso	on(s) to Issu 10% Ow Other (s	wner	
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 04/27/2018							X				below)	респу	
(Street) THOUSAND OAKS CA 91320-1799 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Ind Line)	´						
		Tal	ole I - Non-	-Derivati	ve Se	curitie	s Ac	quired,	Dis	osed o	f, or Be	nefi	cially	Owned				
Date				2. Transacti Date (Month/Day/	Execution Date,		Code (Instr. 5)				, 4 and Securiti Benefic Owned		s ally ollowing	Form:	Direct Indirect I	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) o	or P	rice	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)
Common	Stock		04/27/20	7/2018		A		4,508 ⁽¹⁾ A			\$ <mark>0</mark>	60,15	60,155(2)(3)		D			
			Table II - D (e	erivative e.g., puts										Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	saction (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form Director Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	D) Beneficial Ownershi ect (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	or Nui of	ount mber ares					
Nqso (Right to Buy)	\$177.46	04/27/2018		A		34,702		04/27/2020	(4)	04/27/2028	Common Stock	34	,702	\$0	34,702	2	D	

Explanation of Responses:

- 1. These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.
- 2. These shares include the following RSUs granted under the Company's equity plans: 13,541 RSUs which vest in one installment on 8/1/2018; 1,340 RSUs which vest in one installment on 1/30/2019; 4,477 RSUs which vest in two equal installments of 1,470 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 3. These shares include 1,712 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- 4. These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

<u>/s/ David W. Meline</u> <u>05/01/2018</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.